The SARS coronavirus papain like protease can inhibit IRF3 at a post activation step that requires deubiquitination activity

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Krystal Matthews
    • Other Affiliation: Department of Microbiology and Immunology, University of Maryland at Baltimore
  • Alexandra Schäfer
    • Other Affiliation: 2 Department of Epidemiology, University of North Carolina, 3304 Michael Hooker Research Building, Chapel Hill, NC 27599, USA
  • Alissa Pham
    • Other Affiliation: Department of Microbiology, Icahn School of Medicine at Mt. Sinai, New York, NY 10029, USA. ; NYU Langone Medical Center, Department of Pathology, 538 Medical Science Building, New York, NY 10016, USA
  • Matthew Frieman
    • Other Affiliation: Department of Microbiology and Immunology, University of Maryland at Baltimore
Abstract
  • BackgroundThe outcome of a viral infection is regulated by complex interactions of viral and host factors. SARS coronavirus (SARS-CoV) engages and regulates several innate immune response pathways during infection. We have previously shown that the SARS-CoV Papain-like Protease (PLpro) inhibits type I interferon (IFN) by inhibiting IRF3 phosphorylation thereby blocking downstream Interferon induction. This finding prompted us to identify other potential mechanisms of inhibition of PLpro on IFN induction.Methods We have used plasmids expressing PLpro and IRF3 including an IRF3 mutant that is constitutively active, called IRF3(5D). In these experiments we utilize transfections, chromatin immunoprecipitation, Electro-mobility Shift Assays (EMSA) and protein localization to identify where IRF3 and IRF3(5D) are inhibited by PLpro.ResultsHere we show that PLpro also inhibits IRF3 activation at a step after phosphorylation and that this inhibition is dependent on the de-ubiquitination (DUB) activity of PLpro. We found that PLpro is able to block the type I IFN induction of a constitutively active IRF3, but does not inhibit IRF3 dimerization, nuclear localization or DNA binding. However, inhibition of PLpro’s DUB activity by mutagenesis blocked the IRF3 inhibition activity of PLpro, suggesting a role for IRF3 ubiquitination in induction of a type I IFN innate immune response.ConclusionThese results demonstrate an additional mechanism that PLpro is able to inhibit IRF3 signaling. These data suggest novel innate immune antagonism activities of PLpro that may contribute to SARS-CoV pathogenesis.
Date of publication
Keyword
DOI
Related resource URL
Resource type
  • Article
Rights statement
  • In Copyright
Journal title
  • Virology Journal
Journal volume
  • 11
Journal issue
  • 1
Page start
  • 1
Page end
  • 12
Language
  • English
ISSN
  • 1743-422X
Publisher
  • BioMed Central

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details 12985_2014_Article_209.pdf 2020-04-08 Public Download